Target Validation Information
TTD ID	T68443
Target Name	Matrix metalloproteinase-21 (MMP-21)
Type of Target	Literature-reported
Drug Potency against Target	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Drug Info	IC50 = 5100 nM	[5]
	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	Drug Info	IC50 = 18070 nM	[2]
	GM6001	Drug Info	IC50 = 17 nM	[2]
	IK-862	Drug Info	Ki = 1599 nM	[1]
	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	Drug Info	Ki = 356 nM	[4]
	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Drug Info	IC50 = 1300 nM	[5]
	SR-973	Drug Info	Ki = 190 nM	[3]
	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Drug Info	IC50 = 4300 nM	[5]
References
REF 1	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
REF 2	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
REF 3	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
REF 4	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
REF 5	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.